Journal article
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer
H Fettke, EM Kwan, MM Docanto, P Bukczynska, N Ng, LJK Graham, K Mahon, C Hauser, W Tan, XH Wang, Z Zhao, T Zheng, K Zhou, P Du, J Yu, Y Huang, S Jia, M Kohli, LG Horvath, AA Azad
European Urology | ELSEVIER | Published : 2020
Abstract
Background: The androgen receptor (AR) remains a critical driver in metastatic castration-resistant prostate cancer (mCRPC). Profiling AR aberrations in both circulating DNA and RNA may identify key predictive and/or prognostic biomarkers in the context of contemporary systemic therapy. Objective: To profile AR aberrations in circulating nucleic acids and correlate with clinical outcomes. Design, setting, and participants: We prospectively enrolled 67 mCRPC patients commencing AR pathway inhibitors (ARPIs; n = 41) or taxane chemotherapy (n = 26). Using a first-in-class next-generation sequencing-based assay, we performed integrated cell-free DNA (cfDNA) and cell-free RNA (cfRNA) profiling fr..
View full abstractRelated Projects (2)
Grants
Awarded by National Cancer Institute
Funding Acknowledgements
Heidi Fettke: Australian Government Research Training Program (RTP) scholarship. Edmond M. Kwan: NHMRC postgraduate scholarship. Kate Mahon: Movember/Prostate Cancer Foundation of Australia Clinical Scientist Fellow. Lisa G. Horvath: Astellas Investigator-initiated grant, Cancer Institute NSW Translational Program grant. Arun A. Azad: NHMRC project grant, Victorian Cancer Agency Clinical Research Fellowship, Astellas Investigator-initiated grant. Manish Kohli: National Institute of Health (RO1-CA212097).